atogepant
Trade name: Qulipta
Small moleculeapproved
Approved
Sep 28, 2021
Clinical trial activity
21 trials · 5 clinical orgs · 1 marketing orgs
Phase 1
2
Phase 2
16
Phase 3
17
Phase 4
2
Earliest trial started Sep 1, 2016 (NCT02848326)
Timeline
Indications
Approved for
Mechanism of action
CALCRL antagonist
Approval history
- approvedPriority reviewSep 28, 2021
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F- Mol. weight
- 603.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3991065 ↗
Also known as
- agn-241689
- agn-241689
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06972056 | Phase 4 | Jul 9, 2025 | AbbVie, Mayo Clinic, Patient-Centered Outcomes Research Institute, University of Iowa |
| NCT06810505 | Phase 3 | Feb 13, 2025 | AbbVie |
| NCT06806293 | Phase 3 | Feb 10, 2025 | AbbVie |
| NCT06241313 | Phase 3 | Mar 25, 2024 | AbbVie |
| NCT05748483 | Phase 3 | Oct 7, 2023 | AbbVie |
| NCT05861427 | Phase 3 | Jul 12, 2023 | AbbVie |
| NCT05892757 | Phase 1 | Jul 11, 2023 | AbbVie |
| NCT05707949 | Phase 3 | Jun 5, 2023 | AbbVie |
| NCT05711394 | Phase 3 | May 1, 2023 | AbbVie |
| NCT05216263 | Phase 3 | Nov 1, 2022 | Allergan |
| NCT05264129 | Phase 4 | Mar 7, 2022 | AbbVie |
| NCT04829747 | Phase 3 | Aug 2, 2021 | Allergan |
| NCT04818515 | Phase 1 | Mar 17, 2021 | Allergan |
| NCT04740827 | Phase 3 | Mar 5, 2021 | Allergan |
| NCT04686136 | Phase 3 | Feb 1, 2021 | Allergan |
| NCT04437433 | Phase 3 | Jun 17, 2020 | Allergan |
| NCT03939312 | Phase 3 | May 6, 2019 | Allergan |
| NCT03855137 | Phase 3 | Mar 11, 2019 | Allergan |
| NCT03777059 | Phase 3 | Dec 14, 2018 | Allergan |
| NCT03700320 | Phase 3 | Oct 8, 2018 | Allergan |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 11 | 11 | 2 | 2016 |
| AbbVie | For profit | 10 | 9 | 3 | 2022 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Patient-Centered Outcomes Research Institute | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1